{
    "clinical_study": {
        "@rank": "106061", 
        "arm_group": [
            {
                "arm_group_label": "30 \u00b5g Na-GST-1 + 30 \u00b5g Na-APR-1 (M74)", 
                "arm_group_type": "Experimental", 
                "description": "30 \u00b5g Na-GST-1/Alhydrogel plus 5 \u00b5g GLA-AF co-administered with 30 \u00b5g Na-APR-1 (M74)/Alhydrogel plus 5 \u00b5g GLA-AF"
            }, 
            {
                "arm_group_label": "Hepatitis B vaccine", 
                "arm_group_type": "Active Comparator", 
                "description": "Hepatitis B vaccine co-administered with saline"
            }, 
            {
                "arm_group_label": "100 \u00b5g Na-GST-1 plus 100 \u00b5g Na-APR-1 (M74)", 
                "arm_group_type": "Experimental", 
                "description": "100 \u00b5g Na-GST-1/Alhydrogel plus 5 \u00b5g GLA-AF co-administered with 100 \u00b5g Na-APR-1 (M74)/Alhydrogel plus 5 \u00b5g GLA-AF"
            }
        ], 
        "brief_summary": {
            "textblock": "Na-GST-1 and Na-APR-1 are proteins expressed during the adult stage of the Necator\n      americanus hookworm life cycle that are thought to play a role in the parasite's degradation\n      of host hemoglobin for use as an energy source. Vaccination with recombinant GST-1 or APR-1\n      has protected dogs and hamsters from infection in challenge studies.  This study will\n      evaluate the safety and immunogenicity of co-administering Na-GST-1 and Na-APR-1 to healthy\n      Gabonese adults living in an area of endemic hookworm infection."
        }, 
        "brief_title": "Safety and Immunogenicity of Co-Administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 in Gabonese Adults", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hookworm Infection", 
            "Hookworm Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hookworm Infections", 
                "Ancylostomiasis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Double-blind, randomized, controlled dose-escalation Phase 1 clinical trial in hookworm\n      exposed adults.\n\n      Study site: Centre de Recherches M\u00e9dicales de Lambar\u00e9n\u00e9 Number of participants: 32 in 2\n      cohorts of 16\n\n      Doses of Na-GST-1 to be tested: 30 and 100 \u03bcg Doses of Na-APR-1 to be tested: 30 and 100 \u03bcg\n      Dose of GLA-AF: 5 \u03bcg per antigen\n\n      Cohort 1: 30 \u03bcg of each of the two antigens (Na-GST-1/Alhydrogel\u00ae and Na-APR-1\n      (M74)/Alhydrogel\u00ae) or hepatitis B vaccine; Cohort 2: 100 \u03bcg of each of the two antigens\n      (Na-GST- 1/Alhydrogel\u00ae and Na-APR-1 (M74) /Alhydrogel\u00ae) or hepatitis B vaccine.\n\n      Randomization: Cohort 1: 30 \u03bcg Na-GST-1 + 30 \u03bcg Na-APR-1 (M74) (n = 12) versus Hepatitis B\n      Vaccine/placebo (n = 4) Cohort 2: 100 \u03bcg Na-GST-1 + 100 \u03bcg Na-APR-1 (M74) (n = 12) versus\n      Hepatitis B Vaccine + placebo (n = 4)\n\n      The cohorts will be enrolled in a staggered fashion with safety data assessed prior to the\n      Na-GST-1 and Na-APR-1 dose escalation from 30 to 100 \u00b5g.\n\n      Pre-treatment: Albendazole (400 mg) at least 2 weeks prior to first vaccination\n\n      Immunization schedule: Study days 0, 28 and 180 Route: Intramuscular in the deltoid muscle\n\n      Study duration: approximately 20 months; each participant will be followed for a total of 12\n      months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or females between 18 and 50 years, inclusive, who are long-term residents of\n             Gabon.\n\n          -  Good general health as determined by means of the screening procedure.\n\n          -  Assumed availability for the duration of the trial (12 months).\n\n          -  Willingness to participate in the study as evidenced by signing the informed consent\n             document.\n\n          -  Negative for hookworm during screening, or if found to be infected with hookworm, has\n             completed a course of three doses of albendazole.\n\n        Exclusion Criteria:\n\n          -  Pregnancy as determined by a positive urine hCG (if female).\n\n          -  Participant unwilling to use reliable contraception up until one month following the\n             third immunization (if female and not surgically sterile, abstinent or at least 2\n             years post-menopausal).\n\n          -  Currently lactating and breast-feeding (if female).\n\n          -  Inability to correctly answer all questions on the informed consent comprehension\n             questionnaire.\n\n          -  Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic,\n             rheumatologic, autoimmune, diabetes, or renal disease by history, physical\n             examination, and/or laboratory studies.\n\n          -  Known or suspected immunodeficiency.\n\n          -  Laboratory evidence of liver disease (alanine aminotransferase [ALT] greater than\n             1.25-times the upper reference limit).\n\n          -  Laboratory evidence of renal disease (serum creatinine greater than 1.25-times the\n             upper reference limit, or more than trace protein or blood on urine dipstick\n             testing).\n\n          -  Laboratory evidence of hematologic disease (absolute leukocyte count <3500/mm3;\n             absolute leukocyte count >11.0 x 103/mm3; hemoglobin <10.000 g/dl [females] or <12.0\n             g/dl [males]; or, platelet count <140,000/mm3).\n\n          -  Other condition that in the opinion of the investigator would jeopardize the safety\n             or rights of a volunteer participating in the trial or would render the subject\n             unable to comply with the protocol.\n\n          -  Participation in another investigational vaccine or drug trial within 30 days of\n             starting this study or for the duration of the study.\n\n          -  Volunteer has had medical, occupational, or family problems as a result of alcohol or\n             illicit drug use during the past 12 months.\n\n          -  History of a severe allergic reaction or anaphylaxis.\n\n          -  Severe asthma as defined by the need for daily use of inhalers or emergency\n             room/clinic visit or hospitalization within 6 months of the volunteer's planned first\n             vaccination in the study.\n\n          -  Positive for HCV\n\n          -  Positive ELISA for HBsAg.\n\n          -  Positive for HIV infection\n\n          -  Use of corticosteroids (excluding topical or nasal) or immunosuppressive drugs within\n             30 days of starting this study or expect to use for the duration of the study.\n\n          -  Receipt of a live vaccine within past 4 weeks or a killed vaccine within past 2 weeks\n             prior to entry into the study.\n\n          -  History of a surgical splenectomy.\n\n          -  Receipt of blood products within the 6 months prior to entry into the study.\n\n          -  Previous receipt of a primary series of any hepatitis B vaccine."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02126462", 
            "org_study_id": "HV-001", 
            "secondary_id": "602843-2"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "30 \u00b5g Na-GST-1 + 30 \u00b5g Na-APR-1 (M74)", 
                    "100 \u00b5g Na-GST-1 plus 100 \u00b5g Na-APR-1 (M74)"
                ], 
                "intervention_name": "Na-APR-1 (M74)/Alhydrogel\u00ae", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "30 \u00b5g Na-GST-1 + 30 \u00b5g Na-APR-1 (M74)", 
                    "100 \u00b5g Na-GST-1 plus 100 \u00b5g Na-APR-1 (M74)"
                ], 
                "intervention_name": "Na-GST-1/Alhydrogel\u00ae", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Hepatitis B vaccine", 
                "description": "Hepatitis B vaccine co-administered with saline", 
                "intervention_name": "Hepatitis B vaccine", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Aluminum Hydroxide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Human Hookworm", 
            "Necator americanus", 
            "Hookworm", 
            "Hookworm Disease", 
            "Iron-deficiency anemia", 
            "Soil-transmitted helminth infection", 
            "Neglected Tropical Disease", 
            "Na-APR-1", 
            "Na-GST-1"
        ], 
        "lastchanged_date": "April 29, 2014", 
        "location": {
            "contact": {
                "email": "aadegnika@lambarene.org", 
                "last_name": "Ayola Adegnika, MD", 
                "phone": "+241-0740-6464"
            }, 
            "facility": {
                "address": {
                    "city": "Lambar\u00e9n\u00e9", 
                    "country": "Gabon", 
                    "zip": "BP: 118"
                }, 
                "name": "Centre de Recherches M\u00e9dicales de Lambar\u00e9n\u00e9 Albert Schweitzer Hospital"
            }, 
            "investigator": {
                "last_name": "Ayola Akim Adegnika, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Gabon"
        }, 
        "number_of_arms": "3", 
        "official_title": "Randomized, Controlled, Phase 1 Study to Assess Safety and Immunogenicity of Co-administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 Adjuvanted With Alhydrogel\u00ae and Gluco-pyranosylphospho-lipid A in Gabonese Adults", 
        "overall_official": {
            "affiliation": "Centre de Recherches Medicales de Lambaren\u00e9", 
            "last_name": "Ayola Adegnika, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "European Union: European Commission", 
                "Gabon: Ministry of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To estimate the frequency of vaccine-related adverse events, graded by severity, for each dose of co-administered Na-GST-1 and Na-APR-1 (M74).\nThe frequency of immediate, systemic, and local injection site adverse events will be summarized. Adverse events will be assessed by study team members at 1 hour post-vaccination as well as 1, 3, 7, 14, and 28 days following each vaccination.", 
            "measure": "Vaccine-related Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "Day 360"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02126462"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To determine the doses of Na-GST-1 and Na-APR-1 (M74) that generate the highest IgG antibody responses at Day 194, as determined by indirect enzyme-linked immunosorbent assays (ELISA)", 
                "measure": "IgG response to Na-GST-1 and Na-APR-1 (M74)", 
                "safety_issue": "No", 
                "time_frame": "Day 194"
            }, 
            {
                "description": "To assess and compare the duration of antibody responses to Na- GST-1 and Na-APR-1 (M74).", 
                "measure": "Duration of antibody response to Na-GST-1 and Na-APR-1 (M74)", 
                "safety_issue": "No", 
                "time_frame": "Day 14, 28, 42, 56, 180, 194, 208, 270, 360"
            }, 
            {
                "description": "Exploratory studies of memory B-cell responses against the metabolomics changes before and after Na-GST-1 and NA-APR-1 (M74) vaccine antigens.", 
                "measure": "Exploratory studies of memory B-cell responses", 
                "safety_issue": "No", 
                "time_frame": "Days 14, 28, 42, 56, 180, 194, 208, 270, 360"
            }
        ], 
        "source": "Albert B. Sabin Vaccine Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Albert B. Sabin Vaccine Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}